<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Purple Biotech Ltd — News on 6ix</title>
<link>https://6ix.com/company/purple-biotech-ltd</link>
<description>Latest news and press releases for Purple Biotech Ltd on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 27 Apr 2026 11:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/purple-biotech-ltd" rel="self" type="application/rss+xml" />
<item>
<title>Purple Biotech Announces New Data from CAPTN-3 Platform Tri-specific IM1240</title>
<link>https://6ix.com/company/purple-biotech-ltd/news/purple-biotech-announces-new-data-from-captn-3-platform-tri-specific-im1240</link>
<guid isPermaLink="true">https://6ix.com/company/purple-biotech-ltd/news/purple-biotech-announces-new-data-from-captn-3-platform-tri-specific-im1240</guid>
<pubDate>Mon, 27 Apr 2026 11:00:00 GMT</pubDate>
<description>Data, generated in the lab of Dr. Amir Horowitz of the Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai, demonstrated that all tested patient-derived tumor samples (n=7) responded to IM1240 treatment New data shows that the NKG2A arm significantly enhanced anti-tumor activity in all samples and improved the therapeutic index Immune cell structures known as a hallmark of effective anti-tumor immune response and favorable prognosis, were induced by IM1240 in a patient-derived</description>
</item>
<item>
<title>Purple Biotech Establishes Scientific Advisory Board to Support Development of CAPTN-3 Tri-Specific Antibody Platform</title>
<link>https://6ix.com/company/purple-biotech-ltd/news/purple-biotech-establishes-scientific-advisory-board-to-support-development-of-captn-3-tri-specific-antibody-platform</link>
<guid isPermaLink="true">https://6ix.com/company/purple-biotech-ltd/news/purple-biotech-establishes-scientific-advisory-board-to-support-development-of-captn-3-tri-specific-antibody-platform</guid>
<pubDate>Thu, 23 Apr 2026 11:00:00 GMT</pubDate>
<description>Scientific Advisory Board (SAB) includes experts in the development and approved T-cell engager therapies, supporting CAPTN-3’s advancement toward clinical-stage immunotherapy development SAB leverages expertise in translational science, NK and T cell biology REHOVOT, Israel and BOSTON, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing a next-generation immunotherapy platform designed to maxi</description>
</item>
<item>
<title>Purple Biotech Announces AI Collaboration with Converge Bio to Accelerate Development of its Next-Generation Tri-Specific Antibody Platform</title>
<link>https://6ix.com/company/purple-biotech-ltd/news/purple-biotech-announces-ai-collaboration-with-converge-bio-to-accelerate-development-of-its-next-generation-tri-specific-antibody-platform</link>
<guid isPermaLink="true">https://6ix.com/company/purple-biotech-ltd/news/purple-biotech-announces-ai-collaboration-with-converge-bio-to-accelerate-development-of-its-next-generation-tri-specific-antibody-platform</guid>
<pubDate>Wed, 25 Mar 2026 12:00:00 GMT</pubDate>
<description>Collaboration leverages Converge Bio's proprietary generative AI to design and optimize novel tri-specific antibodies for oncology needs AI-driven development strategy designed to significantly accelerate discovery timelines and enhance molecule quality for drug candidates targeting solid tumors REHOVOT, Israel and BOSTON, Mass., March 25, 2026 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing a next-generation im</description>
</item>
<item>
<title>Purple Biotech Regains Compliance with Nasdaq</title>
<link>https://6ix.com/company/purple-biotech-ltd/news/purple-biotech-regains-compliance-with-nasdaq</link>
<guid isPermaLink="true">https://6ix.com/company/purple-biotech-ltd/news/purple-biotech-regains-compliance-with-nasdaq</guid>
<pubDate>Tue, 17 Mar 2026 11:00:00 GMT</pubDate>
<description>Minimum Bid Price Requirement REHOVOT, Israel, March 17, 2026 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing a next-generation immunotherapy platform designed to maximize anti-cancer potency while minimizing toxicity, today announced that it received confirmation from the Listing Qualifications Department of The Nasdaq Stock Market LLC (the “Listing Qualifications Department”) that the Company had regained comp</description>
</item>
<item>
<title>Purple Biotech Announces CEO Transition</title>
<link>https://6ix.com/company/purple-biotech-ltd/news/purple-biotech-announces-ceo-transition</link>
<guid isPermaLink="true">https://6ix.com/company/purple-biotech-ltd/news/purple-biotech-announces-ceo-transition</guid>
<pubDate>Fri, 13 Mar 2026 12:04:00 GMT</pubDate>
<description>Gil Efron to Step Down as CEO in August 2026 for Health Considerations; Will Continue to Lead Corporate Development REHOVOT, Israel, March 13, 2026 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (NASDAQ/TASE: PPBT), a clinical-stage company developing next-generation cancer therapies, today announced that Gil Efron, Chief Executive Officer, will step down from his role as CEO effective August 2026. Mr. Efron will remain actively involved with the Company, transitioning to lead corporate development and</description>
</item>
<item>
<title>Purple Biotech Announces Plan to Implement ADS Ratio Change</title>
<link>https://6ix.com/company/purple-biotech-ltd/news/purple-biotech-announces-plan-to-implement-ads-ratio-change</link>
<guid isPermaLink="true">https://6ix.com/company/purple-biotech-ltd/news/purple-biotech-announces-plan-to-implement-ads-ratio-change</guid>
<pubDate>Wed, 25 Feb 2026 21:20:00 GMT</pubDate>
<description>ADS Will Begin Trading Reflecting the Ratio Change on March 2, 2026 REHOVOT, Israel, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing a next-generation immunotherapy platform designed to maximize anti-cancer potency while minimizing toxicity, today announced that it intends to change the ratio of American Depositary Shares (“ADSs”) to its ordinary shares, no par value per share (the “ADS Ratio”), fr</description>
</item>
<item>
<title>Purple Biotech Achieves Toxicology Milestone Demonstrating an Expanded Therapeutic Window for CAPTN-3 Platform Tri-specific Antibody, IM1240</title>
<link>https://6ix.com/company/purple-biotech-ltd/news/purple-biotech-achieves-toxicology-milestone-130000041</link>
<guid isPermaLink="true">https://6ix.com/company/purple-biotech-ltd/news/purple-biotech-achieves-toxicology-milestone-130000041</guid>
<pubDate>Wed, 07 Jan 2026 13:00:00 GMT</pubDate>
<description>IM1240 demonstrated improved safety in a toxicology study at doses up to 300-fold higher than a non-capped comparator IM1240's pharmacokinetic profile showed increased systemic exposure and a prolonged circulating half-life enabled by its human serum albumin moiety and capping design IM1240 on track towards first-in-human clinical trials, with regulatory submission planned for the second half of 2026 REHOVOT, Israel, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or the</description>
</item>
<item>
<title>Purple Biotech Reports Positive New Preclinical Data Demonstrating Multi-Arm Anti-Tumor Activity Across Two CAPTN-3 Tri-Specific Antibodies at ESMO Immuno-Oncology Congress 2025</title>
<link>https://6ix.com/company/purple-biotech-ltd/news/purple-biotech-reports-positive-preclinical-120000448</link>
<guid isPermaLink="true">https://6ix.com/company/purple-biotech-ltd/news/purple-biotech-reports-positive-preclinical-120000448</guid>
<pubDate>Thu, 11 Dec 2025 12:00:00 GMT</pubDate>
<description>Data demonstrates the significant and sustained tumor regression achieved by the CAPTN-3 platform across two distinct tri-specific antibodies, IM1240 and IM1305, targeting different tumor antigens Transcriptomic analysis across ~11,000 TCGA samples shows NKG2A expression is strongly associated with tumor expression of 5T4 or TROP2, supporting inclusion of the NKG2A arm in CAPTN-3 designs NKG2A arm significantly contributes to IM1240 anti-cancer immune activity in PD1-resistant patient-derived ex</description>
</item>
<item>
<title>Purple Biotech to Present New Preclinical Data from its CAPTN-3 Tri-Specific Antibody Platform at the European Society of Medical Oncology Immuno-Oncology (ESMO-IO) 2025 Annual Congress</title>
<link>https://6ix.com/company/purple-biotech-ltd/news/purple-biotech-present-preclinical-data-120000180</link>
<guid isPermaLink="true">https://6ix.com/company/purple-biotech-ltd/news/purple-biotech-present-preclinical-data-120000180</guid>
<pubDate>Thu, 04 Dec 2025 12:00:00 GMT</pubDate>
<description>New data showcase the versatility and anti-tumor activity of the CAPTN-3 platform and its unique multi-arm design in treatment-resistant cancers REHOVOT, Israel, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today announced that it will present new preclinical data from its CAPTN-3 platform of conditionally a</description>
</item>
<item>
<title>Purple Biotech Reports Third Quarter 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/purple-biotech-ltd/news/purple-biotech-reports-third-quarter-130000024</link>
<guid isPermaLink="true">https://6ix.com/company/purple-biotech-ltd/news/purple-biotech-reports-third-quarter-130000024</guid>
<pubDate>Fri, 14 Nov 2025 13:00:00 GMT</pubDate>
<description>Initiated development of a second CAPTN-3 tri-specific antibody targeting TROP2 Manufacturing milestone achieved for IM1240, the first tri-specific 5T4-targeting antibody from the CAPTN-3 platform Cash position of $10.5 million as of September 30, 2025, with an anticipated cash runway into the first half of 2027, supporting the development of our CAPTN-3 technology platform through significant milestones REHOVOT, Israel, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or</description>
</item>
<item>
<title>Purple Biotech Achieves Manufacturing Milestone for IM1240, a Tri-Specific Antibody from the CAPTN-3 Platform</title>
<link>https://6ix.com/company/purple-biotech-ltd/news/purple-biotech-achieves-manufacturing-milestone-113300829</link>
<guid isPermaLink="true">https://6ix.com/company/purple-biotech-ltd/news/purple-biotech-achieves-manufacturing-milestone-113300829</guid>
<pubDate>Wed, 29 Oct 2025 11:33:00 GMT</pubDate>
<description>Achieved commercially viable yield for IM1240, positioning the program competitively for future development Validates scalability of the CAPTN-3 tri-specific antibody platform IM1240, the first CAPTN-3 tri-specific antibody targeting the novel tumor-associated antigen 5T4, advances toward first-in-human clinical trials, with an Investigational New Drug (IND) submission planned for 2026 REHOVOT, Israel, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or the “Company”) (NAS</description>
</item>
<item>
<title>Purple Biotech Receives Intention to Grant a European Patent Covering NT219 Combinations with Immunotherapies or MEK Inhibitors to Overcome Tumor Resistance</title>
<link>https://6ix.com/company/purple-biotech-ltd/news/purple-biotech-receives-intention-grant-120000657</link>
<guid isPermaLink="true">https://6ix.com/company/purple-biotech-ltd/news/purple-biotech-receives-intention-grant-120000657</guid>
<pubDate>Wed, 10 Sep 2025 12:00:00 GMT</pubDate>
<description>A Phase 2 study for NT219 in combination with immunotherapy is being conducted in collaboration with the University of Colorado REHOVOT, Israel, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today announced that the Examining Division of the European Patent Office has issued an intention to grant a European</description>
</item>
<item>
<title>Purple Biotech Announces Closing of Up To $18 Million Public Offering $6 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants</title>
<link>https://6ix.com/company/purple-biotech-ltd/news/purple-biotech-announces-closing-18-200000564</link>
<guid isPermaLink="true">https://6ix.com/company/purple-biotech-ltd/news/purple-biotech-announces-closing-18-200000564</guid>
<pubDate>Fri, 05 Sep 2025 20:00:00 GMT</pubDate>
<description>REHOVOT, Israel, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today announced the closing of its previously announced public offering of an aggregate of 5,999,999 of the Company’s American Depositary Shares (ADSs) (or pre-funded warrants in lieu thereof), with each ADS representing 200 ordinary shares, and</description>
</item>
<item>
<title>Purple Biotech Announces Pricing of Up To $18 Million Public Offering</title>
<link>https://6ix.com/company/purple-biotech-ltd/news/purple-biotech-announces-pricing-18-131500193</link>
<guid isPermaLink="true">https://6ix.com/company/purple-biotech-ltd/news/purple-biotech-announces-pricing-18-131500193</guid>
<pubDate>Thu, 04 Sep 2025 13:15:00 GMT</pubDate>
<description>$6 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants REHOVOT, Israel, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today announced the pricing of a public offering of an aggregate of 5,999,999 of the Company’s American</description>
</item>
<item>
<title>Purple Biotech Announces New Data Supporting the Unique Design of CAPTN-3 Tri-Specific Antibody IM1240 in Collaboration with the Icahn School of Medicine at Mount Sinai</title>
<link>https://6ix.com/company/purple-biotech-ltd/news/purple-biotech-announces-data-supporting-110000132</link>
<guid isPermaLink="true">https://6ix.com/company/purple-biotech-ltd/news/purple-biotech-announces-data-supporting-110000132</guid>
<pubDate>Thu, 04 Sep 2025 11:00:00 GMT</pubDate>
<description>Mt. Sinai Principal Investigator, Dr. Amir Horowitz, demonstrates tumor cell death induced by IM1240 in patient-derived treatment-resistant head and neck biopsies Synergistic effects were observed between the NK and the T cell engager arms of IM1240, a unique combination in the CAPTN-3 platform Analysis of approximately 26,000 human transcriptomes suggests that NKG2A expression is consistently accompanied by 5T4 in solid tissues, but not in blood, supporting the design of IM1240 IM1240, the firs</description>
</item>
<item>
<title>Purple Biotech Expands CAPTN-3 Portfolio with IM1305, a Novel Tri-Specific Antibody Targeting TROP2</title>
<link>https://6ix.com/company/purple-biotech-ltd/news/purple-biotech-expands-captn-3-110000450</link>
<guid isPermaLink="true">https://6ix.com/company/purple-biotech-ltd/news/purple-biotech-expands-captn-3-110000450</guid>
<pubDate>Wed, 03 Sep 2025 11:00:00 GMT</pubDate>
<description>Encouraging in-vivo results demonstrate sustained tumor regression with the CD3xTROP2xNKG2A antibody First CAPTN-3 tri-specific antibody, IM1240, targeting the novel tumor associated antigen 5T4 advances toward first-in-human clinical trials, with Investigational New Drug (IND) submission planned for 2026 REHOVOT, Israel, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies tha</description>
</item>
<item>
<title>Purple Biotech to Participate in the H.C. Wainwright 27th Annual Global Investment Conference</title>
<link>https://6ix.com/company/purple-biotech-ltd/news/purple-biotech-participate-h-c-110000649</link>
<guid isPermaLink="true">https://6ix.com/company/purple-biotech-ltd/news/purple-biotech-participate-h-c-110000649</guid>
<pubDate>Wed, 27 Aug 2025 11:00:00 GMT</pubDate>
<description>REHOVOT, Israel, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today announced that the Company's CEO, Gil Efron will participate in a fireside chat and 1x1 investor meeting at the H.C. Wainwright 27th Annual Global Investment Conference, being held September 8-10, 2025. Details are as follows: H.C. Wainwrigh</description>
</item>
<item>
<title>Purple Biotech Reports Second Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/purple-biotech-ltd/news/purple-biotech-reports-second-quarter-110000932</link>
<guid isPermaLink="true">https://6ix.com/company/purple-biotech-ltd/news/purple-biotech-reports-second-quarter-110000932</guid>
<pubDate>Wed, 06 Aug 2025 11:00:00 GMT</pubDate>
<description>Platform validating preclinical data presented at EACR 2025 for CAPTN-3 tri-specific T cell engager show synergistic activity of the platform’s masked CD3, NKG2A, and tumor-associated antigen arms First CAPTN-3 trispecific antibody targeting novel tumor associated antigen, 5T4, advances toward first-in-human clinical trials, with IND submission expected in 2026 Positive Phase 2 data from CM24 study in biomarker-enriched pancreatic ductal adenocarcinoma (PDAC) reported at AACR 2025 NT219 Phase 2</description>
</item>
<item>
<title>Purple Biotech CEO Issues Letter to Shareholders Highlighting Pipeline Progress and Clinical Milestones Achieved in First Half of 2025</title>
<link>https://6ix.com/company/purple-biotech-ltd/news/purple-biotech-ceo-issues-letter-110000627</link>
<guid isPermaLink="true">https://6ix.com/company/purple-biotech-ltd/news/purple-biotech-ceo-issues-letter-110000627</guid>
<pubDate>Wed, 23 Jul 2025 11:00:00 GMT</pubDate>
<description>REHOVOT, Israel, July 23, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today issued the following letter to shareholders from Chief Executive Officer Gil Efron, highlighting the Company’s scientific progress, operational execution, and strategic milestones during the first half of 2025. Dear Shareholders, I am please</description>
</item>
<item>
<title>Purple Biotech Highlights Significant Advantages of the Novel CAPTN-3 Tri-Specific Antibody Platform at the EACR 2025 Annual Congress</title>
<link>https://6ix.com/company/purple-biotech-ltd/news/purple-biotech-highlights-significant-advantages-110000661</link>
<guid isPermaLink="true">https://6ix.com/company/purple-biotech-ltd/news/purple-biotech-highlights-significant-advantages-110000661</guid>
<pubDate>Mon, 23 Jun 2025 11:00:00 GMT</pubDate>
<description>REHOVOT, Israel, June 23, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today announced the presentation of new preclinical data on its novel CAPTN-3 tri-specific antibody platform in a poster presentation at the 2025 Annual Congress of the European Association for Cancer Research (EACR 2025), that was held in Lisbon,</description>
</item>
</channel>
</rss>